Lineage Cell Therapeutics (LCTX) Operating Leases (2014 - 2026)

Lineage Cell Therapeutics' Operating Leases history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 48.77% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 48.77% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 18.46% from the prior year.
• Operating Leases fell to $1.5 million in Q1 2026 per LCTX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $2.9 million in Q4 2022 and bottomed at $1.0 million in Q1 2025.
• The 5-year median for Operating Leases is $1.8 million (2024), against an average of $1.8 million.
• Across the five-year window, Operating Leases surged 57.92% in 2023 and sank 51.16% in 2025, its largest moves.
• Year by year, Operating Leases stood at $2.9 million in 2022, then plunged by 30.8% to $2.0 million in 2023, then plunged by 34.56% to $1.3 million in 2024, then increased by 18.46% to $1.5 million in 2025, then slipped by 1.76% to $1.5 million in 2026.
• Per Business Quant, the three latest LCTX Operating Leases figures stand at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025).